



















Fig. S2 Evaluation of synergism


- Experimental and approved drugs (EAD) at the concentration listed in Table 2 were incubated with cells alone or in combination with 3 μ M TAP20. The effect of TAP20 alone is indicated by the red dashed line. Confluence was measured in all wells when controls reached >90% confluence. Significant differences of growth are indicated by * ($p < 0.05$), ** ($p < 0.01$) and *** ($p < 0.001$).

CB-839**CB-5083****GSK2837808A****5-fluorouracil****YH16899****Bumetanide**


Thapsigargin**AZD3965****Cetuximab****Rapamycin****PLX8394****Flavopiridol**

Seliciclib**Danuserib****SCH772984****Agerafenib****Selumetinib****GZD824**


Halofuginone




AMG PERK 44




NCT-503



V-9302



Bortezomib



Bay876

